Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10

August 3, 2020 |

1 min read

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on Monday, August 10, 2020 and host a conference call at 4:30 p.m. ET to discuss second quarter 2020 results as well as to provide a general business update. Dial-in Number U.S. Dial-In: 877-300-8521 Int’l Dial

Aug. 3, 2020 13:00 UTC

TORRANCE, Calif.--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on Monday, August 10, 2020 and host a conference call at 4:30 p.m. ET to discuss second quarter 2020 results as well as to provide a general business update.

Dial-in Number

U.S. Dial-In: 877-300-8521
Int’l Dial-In: 412-317-6026

Passcode: 10147071

Webcast
http://public.viavid.com/index.php?id=141126

A live webcast of the call will also be available online in the investor relations section of Forte’s website at https://www.fortebiorx.com/ and will be archived there until August 17, 2020.

About Forte

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. Forte plans to advance FB-401 into a randomized Phase 2 clinical trial in mid-2020.

Source: Forte Biosciences, Inc.